Osteoporotic Fractures During Bisphosphonate Drug Holiday

This publication has 11 references indexed in Scilit:

• American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016
  Endocrine Practice, 2016
• Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
  Journal of Bone and Mineral Research, 2015
• Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy
  JAMA Internal Medicine, 2014
• The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group
  Osteoporosis International, 2014
• Long-Term Follow-up of patients on Drug Holiday from Bisphosphonates: Real-World Setting
  Endocrine Practice, 2013
• Bisphosphonate drug holiday: who, when and how long
  Therapeutic Advances in Musculoskeletal Disease, 2013
• BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate
  Journal of Bone and Mineral Research, 2013
• Continuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long?
  New England Journal of Medicine, 2012
• The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
  Journal of Bone and Mineral Research, 2011
• Effects of Continuing or Stopping Alendronate After 5 Years of Treatment
  JAMA, 2006